A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate

Aging Male

Volumn 10, Issue 3, 2007, Pages 155-158

  Minnemann, T ^a   Schubert, M ^a   Hubler D ^b   Gouni Berthold, I ^a   Freude, S ^a   Schumann, C ^a   Oettel, M ^b   Ernst, M ^b   Mellinger, U ^b   Sommer, F ^a,d   Krone, W ^a   Jockenhovel F ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Evangelisches Krankenhaus Herne   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone mineral density; Haematocrit; Lipids; Prostate safety; Testosterone undecanoate

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LEPTIN; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; LABORATORY TEST; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; WAIST HIP RATIO;

EID: 34547937735     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530701437510     Document Type: Article

References (10)

1. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006;65:275-281.
2. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-5434.
3. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005;6:1751-1759.
4. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria. Aging Male 2006;9:221-227.
5. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002;23:419-425.
6. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®). World J Urol 2006;24:639-644.
7. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006;38:61-68.
8. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727-735.
9. Schubert M, Zitzmann M, Yassin AA. Innovation in testosterone therapy for the treatment of male hypogonadism. J Men's Health Gender 2006;3:356-362.
10. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.